发明申请
US20090181393A1 Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy
审中-公开
用于蛋白酶体抑制治疗的患者的鉴定，评估和治疗方法
- 专利标题： Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy
- 专利标题（中）： 用于蛋白酶体抑制治疗的患者的鉴定，评估和治疗方法
-
申请号： US12316756申请日： 2008-12-16
-
公开(公告)号： US20090181393A1公开(公告)日： 2009-07-16
- 发明人: George Mulligan , Barbara M. Bryant , Michael P. Morrissey , Andrew Bolt , Andrew I. Damokosh
- 申请人： George Mulligan , Barbara M. Bryant , Michael P. Morrissey , Andrew Bolt , Andrew I. Damokosh
- 专利权人： Millennium Pharmaceuticals, Inc.
- 当前专利权人： Millennium Pharmaceuticals, Inc.
- 主分类号： C12Q1/68
- IPC分类号： C12Q1/68 ; G01N33/574
摘要：
The present invention is directed to the identification of markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with responsiveness or non-responsiveness to a therapeutic regimen comprising proteasome inhibition. Thus, by examining the expression levels of individual markers and those comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.
信息查询
